Who makes 0.075% capsaicin cream?

0.075% capsaicin cream is developed by Samyang Biopharmaceuticals Corporation.

What development phase is 0.075% capsaicin cream in?

0.075% capsaicin cream is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

0.075% capsaicin cream

Samyang Biopharmaceuticals Corporation · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	0.075% capsaicin cream
Sponsor	Samyang Biopharmaceuticals Corporation
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome (PHASE4)
Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy (PHASE2)
Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy. (PHASE3)
High Definition Transcranial Direct Current Stimulation Motor Cortex Versus Insula (NA)
Motor Unit Abnormalities After Experimentally Induced Sensitization (PHASE4)
Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain (PHASE1, PHASE2)
Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy (PHASE2, PHASE3)
Acute Response Capsaicin Flare Study (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

0.075% capsaicin cream CI brief — competitive landscape report
0.075% capsaicin cream updates RSS · CI watch RSS
Samyang Biopharmaceuticals Corporation portfolio CI